• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 20, 2014

View Archived Issues

Gene therapy has full coffers and is broadening its horizons

Gene therapy's early days included both extreme triumphs and extreme tragedies even by the standards of medicine. Read More

Type 'righter'? Repros: FDA changes key, more needed about Androxal

A curve ball from the FDA for Repros Therapeutics Inc. played foul with the company's shares as investors learned that U.S. regulators have switched the firm's pre-new drug application meeting from a type B to a less-routine type C session in the first half of next month. Read More

Amgen sues to block competing PCSK9 drug from Sanofi/Regeneron

Amgen Inc. is throwing a wrench in the gears advancing Sanofi SA's and Regeneron Pharmaceuticals Inc.'s high cholesterol drug alirocumab, seeking an injunction to block the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor's manufacture and sale over alleged infringement on patents protecting Amgen's own anti-PCSK9 therapy, evolocumab, now under regulatory review. Read More

Multiple markers predict multipotent mesenchymal stem cells

HONG KONG - A multidisciplinary research team from the Singapore-Massachusetts Institute of Technology (MIT) Alliance in Research and Technology (SMART) has identified a unique set of biophysical markers that are predictive for multipotent mesenchymal stromal cells in bone marrow, which should make it easier to develop stem cell-based therapies. Read More

Indian regulator faces lawsuits over pricing caps

NEW DELHI – The Indian drug pricing regulator is caught in a bitter wrangle between the pharmaceutical industry and public health organizations over recent and contradictory government orders that first called for a cap on drug prices and then U-turned. Read More

Cuba to strengthen cooperation with China in biopharma production

BOGOTA, Colombia – Cuban and Chinese authorities are working together to boost the island´s biotech production through a series of bilateral cooperation agreements that have been in place since 2001. Read More

Financings

Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it priced a public offering of 3.95 million shares at $19 per share for gross proceeds of about $75 million. Read More

Stock movers

Read More

Other news to note

Noven Pharmaceuticals Inc., of Miami, said it filed a lawsuit in the U.S. District Court of New Jersey against units of Actavis plc, of Dublin, including Actavis Laboratories FL Inc., Actavis Pharma Inc. and Actavis Inc. alleging infringement of certain Noven patents. Read More

In the clinic

Globeimmune Inc., of Louisville, Colo., reported data from 11 chordoma patients in its phase I trial of GI-6301 at the Connective Tissue Oncology Society meeting in Berlin, showing the Tarmogen candidate, a yeast-brachyury vaccine, was generally well tolerated, immunogenic and showed evidence of clinical activity in both advanced epithelial cancers and chordomas. Read More

Pharma: Other news to note

Roche AG, of Basel, Switzerland, and DKSH Business Unit Healthcare, an Asia-focused market expansion services provider, inked a deal for DKSH to continue providing services for Roche's full pharma product portfolio in Cambodia, Hong Kong, Laos, Malaysia, Myanmar, Singapore, Thailand and Vietnam. Read More

Pharma: In the clinic

Glasoxmithkline plc, of London, said data published in Respiratory Medicine showed positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol), the combination long-acting muscarinic antagonist (LAMA)/long-acting beta2-adrenergic agonist, with the LAMA tiotropium, administered in the Handihaler inhaler, in patients with chronic obstructive pulmonary disease. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the Israeli Weizman Institute have shown that the metabolic effects of jet lag are due in part to the disruption of circadian rhythms of the microbiome. Shift workers as well as frequent travelers across time zones are prone to metabolic problems. Read More

Popular Stories

  • Telomeres and DNA illustration

    23andme founder-led group outbids Regeneron for company

    BioWorld
    The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
  • Today's news in brief

    BioWorld
    BioWorld briefs for June 17, 2025.
  • Sarepta signage

    Elevidys’ second liver death hits Sarepta, sends DMD ripples

    BioWorld
    How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 17, 2025.
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe